Neuropace Inc (NPCE NASDAQ) stock market data APIs
$12.8393
0.11(0.9%)
as of November 6, 2025
Try our APIs with
free plan!
Neuropace Inc Financial Data Overview
Price chart is built with
Anychart
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Prev. Close
12.8393
Open
12.9502
High
13.2606
Low
12.4676
52 wk Range
6.63-18.975
Market Cap
426 M
Shares Outstanding
33 308 K
Revenue
94 864 K
EPS
-0.11
Beta
1.904
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Neuropace Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neuropace Inc data using free add-ons & libraries
Get Neuropace Inc Fundamental Data
Neuropace Inc Fundamental data includes:
- Net Revenue: 94 864 K
- EBITDA: -18 018 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: -0.1959
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neuropace Inc News
New
After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results
(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session ...
NeuroPace raises 2025 revenue and gross margin guidance amid record RNS growth and DIXI wind-down
Earnings Call Insights: NeuroPace (NPCE) Q3 2025 MANAGEMENT VIEW * CEO Joel Becker stated the third quarter delivered record results for NeuroPace, with total revenue reaching $27.4 million, repre...
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.19 per share a year ago. These figures are...
3 Stocks Estimated To Be Trading Below Fair Value In November 2025
As the U.S. stock market experiences a pullback with major indices like the Dow Jones, Nasdaq, and S&P 500 showing declines, investors are increasingly cautious amid mixed earnings reports and fluctua...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
